Protective effects of NAMPT or MAPK inhibitors and NaR on Wallerian degeneration of mammalian axons.

Animals Armadillo Domain Proteins / metabolism Axons / pathology Cytoskeletal Proteins / metabolism Humans Mammals / metabolism NAD / metabolism Nerve Degeneration / pathology Nicotinamide Phosphoribosyltransferase / antagonists & inhibitors Nicotinamide-Nucleotide Adenylyltransferase / metabolism Protein Kinase Inhibitors Wallerian Degeneration / metabolism
NAD(+) NMNAT2 Neurodegeneration Neuropathy Niacin SARM1

Journal

Neurobiology of disease
ISSN: 1095-953X
Titre abrégé: Neurobiol Dis
Pays: United States
ID NLM: 9500169

Informations de publication

Date de publication:
09 2022
Historique:
received: 19 04 2022
revised: 14 06 2022
accepted: 25 06 2022
pubmed: 3 7 2022
medline: 27 7 2022
entrez: 2 7 2022
Statut: ppublish

Résumé

Wallerian degeneration (WD) is a conserved axonal self-destruction program implicated in several neurological diseases. WD is driven by the degradation of the NAD

Identifiants

DOI: 10.1016/j.nbd.2022.105808 PMID: 35779777 PMC: PMC10621467
pubmed: 35779777
pii: S0969-9961(22)00200-5
doi: 10.1016/j.nbd.2022.105808
pmc: PMC10621467
mid: NIHMS1938713
pii:
doi:

Substances chimiques

Armadillo Domain Proteins 0
Cytoskeletal Proteins 0
Protein Kinase Inhibitors 0
NAD 0U46U6E8UK
Nicotinamide Phosphoribosyltransferase EC 2.4.2.12
Nicotinamide-Nucleotide Adenylyltransferase EC 2.7.7.1

Types de publication

Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S. Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

105808

Subventions

Organisme : NEI NIH HHS
ID : R01 EY028039
Pays : United States
Organisme : NINDS NIH HHS
ID : R01 NS114397
Pays : United States

Informations de copyright

Copyright © 2022. Published by Elsevier Inc.

Références

Respir Res. 2017 Apr 24;18(1):71
pubmed: 28438162
Curr Opin Neurobiol. 2020 Aug;63:59-66
pubmed: 32311648
Elife. 2016 Oct 13;5:
pubmed: 27735788
Br J Cancer. 2015 Jun 30;113(1):12-9
pubmed: 26086878
Ann Clin Transl Neurol. 2020 May;7(5):742-756
pubmed: 32302063
Neuron. 2017 Mar 22;93(6):1334-1343.e5
pubmed: 28334607
Proc Natl Acad Sci U S A. 2013 Mar 5;110(10):4039-44
pubmed: 23431164
Nature. 2020 Dec;588(7839):658-663
pubmed: 33053563
Front Mol Biosci. 2021 Jul 08;8:703532
pubmed: 34307460
Science. 2012 Jul 27;337(6093):481-4
pubmed: 22678360
Mol Neurodegener. 2019 Nov 27;14(1):44
pubmed: 31775817
Neurobiol Dis. 2020 Feb;134:104678
pubmed: 31740269
Neuron. 2017 Jun 21;94(6):1142-1154.e6
pubmed: 28641113
Front Pharmacol. 2020 May 12;11:656
pubmed: 32477131
Biochim Biophys Acta. 2016 Dec;1864(12):1787-1800
pubmed: 27374990
Neuroscience. 2015 Apr 16;291:230-40
pubmed: 25684751
Proc Natl Acad Sci U S A. 2013 Mar 5;110(10):4045-50
pubmed: 23431148
Exp Eye Res. 2018 Jun;171:54-61
pubmed: 29526794
Nat Rev Neurosci. 2020 Apr;21(4):183-196
pubmed: 32152523
J Neuroinflammation. 2012 Apr 10;9:66
pubmed: 22490786
Brain. 2016 Apr;139(Pt 4):1094-105
pubmed: 26912636
J Biol Chem. 2018 Dec 7;293(49):18933-18943
pubmed: 30333228
Exp Neurol. 2019 Nov;321:113040
pubmed: 31445042
Annu Rev Neurosci. 2010;33:245-67
pubmed: 20345246
Proc Natl Acad Sci U S A. 2018 Sep 11;115(37):E8746-E8754
pubmed: 30150401
Neuron. 2021 Apr 7;109(7):1118-1136.e11
pubmed: 33657413
iScience. 2019 May 31;15:452-466
pubmed: 31128467
Int J Cancer. 2012 Jan 1;130(1):223-33
pubmed: 21351087
Brain. 2016 Dec;139(Pt 12):3092-3108
pubmed: 27797810
Neuron. 2012 Jun 21;74(6):1015-22
pubmed: 22726832
Sci Rep. 2017 Feb 13;7:42367
pubmed: 28205555
J Cell Biol. 2011 Sep 5;194(5):751-64
pubmed: 21893599
Neurobiol Dis. 2014 Sep;69:108-16
pubmed: 24878510
Sci Transl Med. 2017 Aug 16;9(403):
pubmed: 28814543
Curr Biol. 2017 Mar 20;27(6):784-794
pubmed: 28262487
Int Immunopharmacol. 2020 Dec;89(Pt A):107032
pubmed: 33045576
Cell Rep. 2020 Aug 4;32(5):107999
pubmed: 32755591
J Peripher Nerv Syst. 2017 Sep;22(3):162-171
pubmed: 28485482
Cell. 2015 Jan 15;160(1-2):161-76
pubmed: 25594179
Nat Rev Neurosci. 2014 Jun;15(6):394-409
pubmed: 24840802
J Med Chem. 2015 Jan 8;58(1):401-18
pubmed: 25341110
Cell Death Differ. 2015 May;22(5):731-42
pubmed: 25323584
Cell Rep. 2015 Dec 22;13(11):2539-2552
pubmed: 26686637
PLoS Biol. 2010 Jan 26;8(1):e1000300
pubmed: 20126265
iScience. 2022 Jan 25;25(2):103812
pubmed: 35198877
Proc Natl Acad Sci U S A. 2018 Oct 16;115(42):10654-10659
pubmed: 30257945
Exp Neurol. 2021 Nov;345:113842
pubmed: 34403688
Elife. 2020 Nov 13;9:
pubmed: 33185189
J Cell Biol. 2022 Feb 7;221(2):
pubmed: 34935867
Nat Neurosci. 2009 Apr;12(4):387-9
pubmed: 19287387
J Neurosci. 2018 Apr 18;38(16):4031-4047
pubmed: 29567804
Neurobiol Dis. 2012 May;46(2):393-401
pubmed: 22353563
PLoS Biol. 2016 Jun 02;14(6):e1002472
pubmed: 27254664
Science. 2015 Apr 24;348(6233):453-7
pubmed: 25908823
Exp Neurol. 2020 Jul;329:113252
pubmed: 32087251
Hum Mol Genet. 2012 Jan 15;21(2):251-67
pubmed: 22027994
Curr Opin Neurol. 2019 Dec;32(6):786-795
pubmed: 31633494
Curr Biol. 2018 Feb 5;28(3):421-430.e4
pubmed: 29395922

Auteurs

Athanasios S Alexandris (AS)

Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. Electronic address: a.alexandris@jhmi.edu.

Jiwon Ryu (J)

Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Labchan Rajbhandari (L)

Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Robert Harlan (R)

The Molecular Determinants Center and Core, Johns Hopkins All Children's Hospital, St. Petersburg, FL, USA.

James McKenney (J)

Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Yiqing Wang (Y)

Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Susan Aja (S)

The Molecular Determinants Center and Core, Johns Hopkins All Children's Hospital, St. Petersburg, FL, USA.

David Graham (D)

The Molecular Determinants Center and Core, Johns Hopkins All Children's Hospital, St. Petersburg, FL, USA.

Arun Venkatesan (A)

Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Vassilis E Koliatsos (VE)

Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA. Electronic address: koliat@jhmi.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Protective effects of NAMPT or MAPK inhibitors...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines à domaine armadillo › Protective effects of NAMPT or MAPK inhibitors...
questionsmedicales.fr › Cellules › Neurones › Neurofibres › Axones › Protective effects of NAMPT or MAPK inhibitors...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines du cytosquelette › Protective effects of NAMPT or MAPK inhibitors...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Protective effects of NAMPT or MAPK inhibitors...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Protective effects of NAMPT or MAPK inhibitors...
questionsmedicales.fr › Acides nucléiques, nucléotides et nucléosides › Nucléotides › Ribonucléotides › Nucléotides adényliques › NAD › Protective effects of NAMPT or MAPK inhibitors...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Dégénérescence nerveuse › Protective effects of NAMPT or MAPK inhibitors...
questionsmedicales.fr › Enzymes et coenzymes › Enzymes › Transferases › Glycosyltransferase › Pentosyltransferases › Nicotinamide phosphoribosyltransferase › Protective effects of NAMPT or MAPK inhibitors...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines nucléaires › Protéines liant le poly-adp-ribose › Nicotinamide nucleotide adenylyltransferase › Protective effects of NAMPT or MAPK inhibitors...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Mécanismes moléculaires de l'action pharmacologique › Antienzymes › Inhibiteurs de protéines kinases › Protective effects of NAMPT or MAPK inhibitors...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Dégénérescence nerveuse › Dégénérescence wallerienne › Protective effects of NAMPT or MAPK inhibitors...